We are live on ! Find out more
AEON icon

AEON Biopharma
AEON

81 hedge funds and large institutions have $222M invested in AEON Biopharma in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 3 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 3

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

11% more funds holding

Funds holding: 73 → 81 (+8)

8% more capital invested

Capital invested by funds: $205M → $222M (+$17.1M)

0.08% more ownership

Funds ownership: 1.09% → 1.17% (+0.08%)

Holders
81
Holders Change
+8
Holders Change %
+10.96%
% of All Funds
1.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
18
Reduced
3
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$4.55M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$2.57M
3
Calamos Advisors
Calamos Advisors
Illinois
+$2.46M
4
MF
Magnetar Financial
Illinois
+$1.81M
5
WRBC
W.R. Berkley Corp
Connecticut
+$955K

Top Sellers

Rank Fund Capital Flow
1
PMAM
Picton Mahoney Asset Management
Ontario, Canada
-$3.43M
2
TCM
Tegean Capital Management
New York
-$491K
3
UOC
UBS O'Connor
Illinois
-$470K
4
Citigroup
Citigroup
New York
-$245K
5
OCAM
Owl Creek Asset Management
New York
-$245K
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
26
AQR Arbitrage
Connecticut
$3.13M +$496K +701 +19%
WA
27
Whitebox Advisors
Minnesota
$2.96M – – –
State of Wisconsin Investment Board
28
State of Wisconsin Investment Board
Wisconsin
$2.83M – – –
Goldman Sachs
29
Goldman Sachs
New York
$2.73M – – –
CCA
30
Castle Creek Arbitrage
Colorado
$2.51M – – –
KL
31
KIM LLC
Kansas
$2.46M – – –
Calamos Advisors
32
Calamos Advisors
Illinois
$2.46M +$2.46M +3,472 New
Alyeska Investment Group
33
Alyeska Investment Group
Illinois
$2.36M – – –
CSS
34
Cubist Systematic Strategies
Connecticut
$2.24M +$379K +535 +20%
GCL
35
Glazer Capital LLC
New York
$2.22M +$2.13K +3 +0.1%
Nomura Holdings
36
Nomura Holdings
Japan
$2.22M – – –
Balyasny Asset Management
37
Balyasny Asset Management
Illinois
$2.2M +$232K +328 +12%
CF
38
Cantor Fitzgerald
New York
$1.68M – – –
FCM
39
Farallon Capital Management
California
$1.48M – – –
DCM
40
Dupont Capital Management
Delaware
$1.48M – – –
CL
41
CSS LLC
Illinois
$1.23M +$225K +318 +22%
WRBC
42
W.R. Berkley Corp
Connecticut
$1.2M +$955K +1,348 +387%
MCM
43
Moore Capital Management
New York
$985K – – –
MTCM
44
Mint Tower Capital Management
Netherlands
$955K +$954K +1,347 New
AC
45
Athos Capital
Hong Kong
$880K – – –
CC
46
Centiva Capital
New York
$822K – – –
Ohio Public Employees Retirement System (OPERS)
47
Ohio Public Employees Retirement System (OPERS)
Ohio
$741K – – –
RL
48
RPO LLC
Connecticut
$670K +$669K +944 New
SSA
49
Schonfeld Strategic Advisors
New York
$645K -$155K -219 -19%
ASM
50
ATW SPAC Management
New York
$621K +$620K +875 New
1
2
3 4

AEON Hedge Fund Activity: Q3 2022 in Review

81 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma (AEON) for Q3 2022, worth a combined $222M — up 8.3% from $205M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AEON positions and 5 closed out — a net gain of 8 holders — while 18 added to existing stakes and 3 trimmed.

The largest buyer was BNP Paribas Financial Markets, opening a new position worth an estimated $4.55M. The largest seller was Picton Mahoney Asset Management, exiting entirely with an estimated $3.43M sold.

  • 81 institutional investors held AEON Biopharma (AEON) as of Q3 2022, up from 73 in Q2 2022.
  • Funds reported $222M of AEON Biopharma stock for Q3 2022, up 8.3% quarter-over-quarter.
  • 13 funds opened new AEON Biopharma positions in Q3 2022 and 5 closed out, a net change of +8 holders.
  • The largest AEON Biopharma buyer in Q3 2022 was BNP Paribas Financial Markets, an estimated $4.55M added.
  • The largest AEON Biopharma seller in Q3 2022 was Picton Mahoney Asset Management, an estimated $3.43M sold.

Based on aggregated 13F filings for Q3 2022.